Noninvasive Ventilation of Patients with Acute Respiratory Distress Syndrome: Insights from the LUNG SAFE Study by Bellani, Giacomo et al.
Non-invasive Ventilation of Patients with ARDS: Insights from the
LUNG SAFE Study
Bellani, G., Laffey, J. G., Pham, T., Madotto, F., Fan, E., Brochard, L., ... Pesenti, A. (2016). Non-invasive
Ventilation of Patients with ARDS: Insights from the LUNG SAFE Study. American Journal of Respiratory and
Critical Care Medicine. DOI: 10.1164/rccm.201606-1306OC
Published in:
American Journal of Respiratory and Critical Care Medicine
Document Version:
Peer reviewed version
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
Copyright © 2016 by the American Thoracic Society
The final publication is available at http://www.atsjournals.org/doi/10.1164/rccm.201606-1306OC#.WAnbsPkrJhE
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:15. Feb. 2017
1 
 
Non-invasive ventilation of patients with ARDS: Insights from the LUNG SAFE 
Study 
 
Authors 
Giacomo Bellani, MD, PhD1 
John G. Laffey, MD, MA2 
Tài Pham, MD, 3 
Fabiana Madotto, PhD4 
Eddy Fan, MD, PhD 5 
Laurent Brochard, MD, PhD 6  
Andres Esteban, MD, PhD 7 
Luciano Gattinoni, MD, FRCP 8 
Vesna Bumbasirevic MD, PhD 9 
Lise Piquilloud, MD10 
Frank van Haren, MD, PhD 11 
Anders Larsson, MD, PhD12  
Daniel F. McAuley, MD, PhD 13 
Philippe R. Bauer, MD, PhD14 
Yaseen M Arabi, MD15  
Marco Ranieri, MD 16 
Massimo Antonelli, MD 17 
Gordon D. Rubenfeld, MD MSc18 
B. Taylor Thompson, MD, PhD 19 
Hermann Wrigge, MD, PhD 20 
Arthur S. Slutsky, MD, PhD 21 
2 
 
Antonio Pesenti, MD 22 
On behalf of the LUNG SAFE Investigators and the ESICM Trials Group 
1 Department of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy and Department 
of Emergency and Intensive Care, San Gerardo Hospital, Monza, Italy;  
2 Departments of Anesthesia and Critical Care Medicine, Keenan Research Centre for Biomedical 
Science, St Michael’s Hospital, and Departments of Anesthesia, Physiology and Interdepartmental 
division of Critical Care Medicine, University of Toronto, Canada;  
3AP-HP, Hôpital Tenon, Unité de Réanimation médico-chirurgicale, Pôle Thorax Voies aériennes, 
Groupe hospitalier des Hôpitaux Universitaires de l’Est Parisien, Paris, France; UMR 1153, Inserm, 
Sorbonne Paris Cité, ECSTRA Team, Université Paris Diderot, Paris, France; UMR 915, Inserm, 
Université Paris Est Créteil, Créteil, France. 
4 Research Centre on Public Health, Department of Medicine and Surgery , University of Milano-
Bicocca, Milan, Italy; 
5 Department of Medicine, University Health Network and Mount Sinai Hospital; and 
Interdepartmental Division of Critical Care Medicine and Institute of Health Policy, Management 
and Evaluation, University of Toronto, Toronto, Canada;  
6 Keenan Research Centre, Li Ka Shing Knowledge Institute, St Michael’s Hospital, Toronto, 
Canada and Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, 
Canada;  
7 Hospital Universitario de Getafe, CIBER de Enfermedades Respiratorias, Madrid, Spain. 
8 Department of Anesthesiology, Emergency and Intensive Care Medicine Universitätsmedizin 
Göttingen, Robert Koch Strasse 40, 37073, Göttingen, Germany 
9 School of Medicine University of Belgrade, Serbia and Department of Anesthesia and Intensive 
Care, Emergency Center, Clinical Center of Serbia 
3 
 
10 Adult Intensive Care and Burn Unit, University Hospital of Lausanne, Lausanne, Switzerland and 
Department of Medical Intensive Care, University Hospital of Angers, Angers, France 
11 Intensive Care Unit, The Canberra Hospital, and Australian National University, 
Canberra, Australia; 
12 Section of Anesthesiology and Intensive Care, Department of Surgical Sciences, Uppsala 
University, Uppsala, Sweden; 
13 Centre for Experimental Medicine, Queen's University of Belfast, Wellcome-Wolfson Institute 
for Experimental Medicine, Belfast and Regional Intensive Care Unit, Royal Victoria Hospital, 
Grosvenor Road, Belfast, Northern Ireland; 
14 Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN 55905, USA 
15 King Saud Bin Abdulaziz University for Health Sciences and King Abdullah's International 
Medical Research Center, Riyadh, Saudi Arabia 
16SAPIENZA Università di ROMA, Dipartimento di Anestesia e Rianimazione, Policlinico 
Umberto I,  Viale del Policlinico 155, 00161 Roma, Italy.  
17 Department of Anesthesiology and Intensive Care, Sacro Cuore Catholic University, A. Gemelli 
Hospital, Rome, Italy 
18Sunnybrook Health Sciences Center and the University of Toronto Interdepartmental Division of 
Critical Care Medicine  
19Division of Pulmonary and Critical Care, Department of Medicine, Massachusetts General 
Hospital, Harvard Medical School, Boston, Massachusetts, USA; 
20Department of Anesthesiology and Intensive Care Medicine, University of Leipzig, Liebigstr. 20, 
D-04103 Leipzig, Germany. 
21 Keenan Research Center at the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, the 
Interdepartmental Division of Critical Care Medicine, and the Department of Medicine, 
University of Toronto, Toronto, Canada. 
4 
 
22  Dipartimento di Anestesia, Rianimazione ed Emergenza Urgenza, Fondazione IRCCS Cà 
Granda-Ospedale Maggiore Policlinico and Dipartimento di Fisiopatologia Medico-Chirurgica e dei 
Trapianti, Università degli Studi di Milano, Milan, Italy. 
 
 
Corresponding Author: John G. Laffey, Departments of Anesthesia and Critical Care Medicine, 
Keenan Research Centre for Biomedical Science, St Michael’s Hospital, University of Toronto, 
CANADA.  E-mail: j.laffey@smc.ca  Phone: 1-416-864-5071 
Source of support: This work was funded and supported by the European Society of Intensive 
Care Medicine (ESICM), Brussels, Belgium, by St Michael’s Hospital, Toronto, Canada, and by the 
University of Milan-Bicocca, Monza, Italy. 
Running head: Non-invasive ventilation of patients with ARDS 
Total word count: 3392  
At a Glance Commentary 
Scientific Knowledge on the Subject: Non-invasive ventilation (NIV) is used to treat patients with 
Acute Respiratory Distress Syndrome (ARDS). Current worldwide practice in the use of this 
technique, its implications for patients’ management, and association with outcome are poorly 
understood. The Berlin definition of ARDS is unclear in regard to the severity classification of 
patients with NIV. 
 What This Study Adds to the Field: NIV is used in about 15% patients with ARDS, irrespective 
of the severity of hypoxemia. Classification of ARDS severity in NIV patients based on PaO2/FiO2 
ratio had management and prognostic significance. Use of NIV, in comparison with invasive 
ventilation has important implications for patients’ management. While mortality rate was low in 
patients successfully managed with NIV, patients who failed NIV had a high mortality. NIV may be 
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associated with a worse ICU outcome than invasive mechanical ventilation in moderate to severe 
ARDS. 
 
This article has an online data supplement, which is accessible from this issue's table of content 
online at http://www.atsjournals.org  
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Abstract 
Background: Non-invasive ventilation (NIV) is increasingly used in patients with Acute 
Respiratory Distress Syndrome (ARDS). Whether, during NIV, the categorization of ARDS 
severity based on the PaO2/FiO2 Berlin criteria is useful is unknown. The evidence supporting NIV 
use in patients with ARDS remains relatively sparse.  
Methods: The Large observational study to UNderstand the Global impact of Severe Acute 
respiratory FailurE (LUNG SAFE) study described the management of patients with ARDS. This 
sub-study examines the current practice of NIV use in ARDS, the utility of the PaO2/FiO2 ratio in 
classifying patients receiving NIV and the impact of NIV on outcome. 
Results: Of 2,813 patients with ARDS, 436 (15.5%) were managed with NIV on days 1 and 2, with 
a similar proportion in each severity category. Classification of ARDS severity based on PaO2/FiO2 
ratio was associated with an increase in intensity of ventilatory support, NIV failure, and ICU 
mortality. NIV failure occurred in 37.5% of patients (22.2% in mild, 42.3% in moderate and 47.1% 
in severe ARDS). Hospital mortality in patients with NIV success and failure was 16.1 % and 
45.4%, respectively. NIV use was independently associated with increased ICU (HR 1.446; [1.159-
1.805]), but not hospital mortality. In a propensity matched analysis, ICU mortality was higher in 
NIV than invasively ventilated patients with a PaO2/FiO2 lower than 150 mmHg. 
Conclusions: NIV was used in 15% of patients with ARDS, irrespective of severity category. NIV 
appears to be associated with higher ICU mortality in patients with a PaO2/FiO2 lower than 150 
mmHg. 
Trial Registration: ClinicalTrials.gov NCT02010073 
Abstract word count: 249 
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Introduction 
Non-invasive ventilation (NIV) has become an established approach in the management of patients 
with acute respiratory failure, with strong evidence for its benefits in patients with acute 
exacerbations of chronic obstructive pulmonary disease (1-3) and cardiogenic pulmonary edema 
(4). NIV is not uncommonly used in the management of patients with Acute Respiratory Distress 
Syndrome (ARDS) {Antonelli, 2007 #5;Walkey, 2013 #49}, as evidenced by its formal recognition 
in the Berlin criteria for ARDS introduced in 2012 (6).  
 
Potential advantages of NIV in the management of patients with ARDS are mainly related to the 
avoidance of complications linked to sedation, muscle paralysis, and ventilator-associated 
complications associated with endotracheal intubation and invasive mechanical ventilation (MV) 
(7). Initially, the use of NIV in patients with ARDS focused on immunocompromised patients such 
as those with hematologic malignancies (8-12). However, NIV has been used in a broader selection 
of ARDS patients (13). Of concern, the evidence supporting NIV use in patients with ARDS is 
based on relatively small samples (5, 14). Moreover, in most studies, patients treated with NIV were 
compared to patients treated with oxygen administration (15) or to historical cohorts (16).  
 
A number of concerns exist regarding the use of NIV in patients with ARDS. The subgroup of 
ARDS most likely to benefit from NIV remains unclear. While some literature suggests that NIV 
may best be reserved for patients with mild ARDS (i.e. patients with a PaO2/FiO2 ratio of 200-300 
mmHg) (5, 14, 17, 18), it is not always the case in practice (19). While some factors leading to NIV 
failure in patients with ARDS are better understood, relatively few patients have been studied to 
date (20, 21). The impact of NIV on outcome in ARDS is therefore not well understood. In 
particular, concerns have been raised regarding the impact of prolonged NIV in the absence of 
respiratory status improvement, potentially delaying tracheal intubation and invasive MV (19, 20, 
22, 23). Finally, the recent Berlin definition of ARDS does not specify whether all patients with 
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ARDS managed with NIV should be classified as all having ‘mild’ ARDS or whether the 
PaO2/FiO2 ratio severity stratification is more appropriate (24).  
 
For these reasons, a key pre-specified secondary aim of the Large observational study to 
UNderstand the Global impact of Severe Acute respiratory FailurE (LUNG SAFE) (25) study was 
to describe the current practice of the use of NIV in ARDS and to determine its impact on patients’ 
management, the incidence of and risk factors leading to NIV failure and the relationship between 
NIV and patient outcome.   
The primary objective was to determine the proportion of ARDS patients managed with NIV on 
days 1 and 2. This period was chosen to avoid classifying patients as treated with NIV if this 
treatment was applied only for a very short period of time. Secondary objectives included: the 
utility of the PaO2/FiO2 ratio severity categories in the classification of NIV patients; characteristics 
of patients managed with NIV; ventilatory settings used in these patients; factors associated with 
NIV failure; and the association between NIV use and mortality in patients with ARDS. 
 
 
METHODS (word count=535) 
LUNG SAFE was a prospective, observational, international multi-centre cohort study. Detailed 
methods have been published elsewhere (25), and are also available in the online data supplement. 
 
Patients, Study Design and Data Collection 
Patients receiving were enrolled in the participating ICUs for four consecutive weeks. Exclusion 
criteria were: age<16 years or inability to obtain informed consent. Following enrollment, patients 
were evaluated daily for Acute Hypoxemic Respiratory Failure (AHRF), defined as: (1) 
PaO2/FiO2≤300 mmHg while on invasive MV or NIV with end expiratory pressure ≥5 cmH2O (2) 
new radiological pulmonary parenchymal abnormalities. For patients fulfilling AHRF criteria a 
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more detailed set of data was recorded, to determine whether the patient fulfilled the Berlin criteria 
for ARDS. 
 
Data on arterial blood gases, type of ventilatory support/settings and Sequential Organ Failure 
Assessment (SOFA) score were collected on selected days during the ICU stay. Data were collected 
once per day, as close as possible to 10 AM. Data on ventilatory settings were recorded 
simultaneously with arterial blood gas analysis. Decisions to withhold or withdraw life sustaining 
treatments and their timing were recorded. ICU and hospital survival were collected at the time of 
discharge, censored at 90 days after enrollment. 
We assessed clinician recognition of ARDS at two time points: on day 1 of study entry, and when 
patients exited the study. ARDS was deemed to have been clinician-recognized if either question 
was answered positively. 
 
NIV Patient Cohort 
We restricted analyses to the subset of patients (93%) fulfilling ARDS criteria on day 1 or 2 from 
onset of AHRF. Patients were classified as “NIV patients” if they received NIV on day 1 and 2 of 
ARDS. Patients were classified as “invasive-MV patients” if they received invasive-MV on day 1 
and/or day 2 of ARDS (Table E1 in the online data supplement).  
 “NIV” definition encompassed all forms of patient interface and ventilatory modes. High flow 
oxygen therapy was not included. Since data were collected once per day and the duration of NIV 
session was not recorded, patients (n=81) switched from NIV to invasive-MV during the first 24 
hours (i.e. before the day 2 data collection) were classified in the invasive-MV group as we 
considered that, in these patients, the NIV session may have been too short to be meaningful. 
“NIV failure” was defined as the need to switch to invasive-MV after the first 24 hours (i.e. after 
the day 2 data collection). We limited the comparison of NIV “success” and “failure” groups to 
patients without treatment limitation (whose definition encompassed all forms of treatment 
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limitations, without further specification) unless this occurred after institution of invasive-MV (see 
also statistical analysis).  
 
Statistical Analysis 
For continuous variables, we reported median with interquartile range (IQR) or mean with standard 
deviation (SD), and for categorical variables we reported proportions. Student’s t, ANOVA, 
Wilcoxon rank sum, Kruskal–Wallis, Chi-Square or Fisher tests were used when appropriate.  
Multivariate Cox proportional hazard models were applied to investigate the relationship between 
potential covariates and outcomes (ICU and hospital mortality, NIV failure). Propensity score 
matching method was used to evaluate the possible different treatment effects (invasive-MV and 
NIV) on survival (Table E2, in the online data supplement). Patients were matched (1:1 match 
without replacement), using a caliper of 0.2 SD of the logit of the propensity score. For all tests, a 
two-sided α of 0.05 was considered significant. The analyses were performed using SAS and R 
software. 
 
 
RESULTS 
 
Incidence of NIV use 
A total of 459 ICUs enrolled patients in the study and 422 enrolled patients with ARDS. In the 
ICUs enrolling ARDS, 207 (49.1 %) used NIV, on days 1 and 2, in at least one patient. Of a total of 
2,813 patients with ARDS within two days from AHRF onset, 436 (15.5%) were managed with 
NIV on days 1 and 2 (Figure 1).  
CPAP was used in 28.2% of patients in the NIV group (Table 1), while the remaining patients were 
managed with pressure cycled modes. 
Classification of NIV Patients 
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Also in patients managed with NIV, classification of ARDS severity in mild moderate and severe 
according to the PaO2/FiO2 bands proposed by the Berlin definition, was associated with a step-
wise increase in PEEP and FiO2 (Table 1). Greater ARDS severity category was associated with an 
increase in clinician recognition of ARDS, and a worsening in outcomes, including ICU length of 
stay, ICU mortality, and non-significant increase in hospital mortality (Table 2). Increasing ARDS 
severity category was associated with a significant increase in NIV failure in patients without pre-
intubation treatment limitations (from 22.2% to 42.3% to 47.1%, p=0.008). 
Of interest, the use of NIV did not vary significantly among mild (14.3%), moderate (17.3%) and 
severe (13.2 %) ARDS (Table 1). 
Baseline characteristics of NIV patients  
NIV patients, in comparison with invasive-MV patients, were older with lower non-pulmonary 
SOFA scores, both in the whole population (3 ± 3 vs 7 ± 4; p<0.001) and across the different 
severity categories (Table 1).  
NIV patients had a higher prevalence of chronic renal failure, congestive heart failure and COPD 
than invasive-MV patients (Table 1). The prevalence of immunosuppression and/or malignancies 
did not differ between the two groups. Clinician recognition of ARDS was significantly lower in 
NIV patients compared to invasive-MV patients (Table 2). The use of NIV was independently 
associated with a lower recognition of ARDS by clinicians (odds ratio 0.585, confidence interval 
95%: 0.45-0.76) (Table E3 in the online data supplement). There were no differences in treatment 
limitation rates in NIV versus invasive-MV patients. 
 
Effect of NIV versus invasive MV on ventilation and gas exchange 
NIV patients had significantly lower levels of PEEP, and higher respiratory rates than invasive-MV 
patients.  In NIV patients, measured tidal volumes and minute ventilation were greater than in 
invasive-MV patients, and did not significantly change with greater ARDS severity (Table 1). 
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At ARDS onset, PaO2/FiO2 ratio was not different between the NIV and invasive-MV patients 
(Table 1). PaO2/FiO2 ratios improved more rapidly in the patients treated with invasive-MV (Figure 
2B and E1). Baseline PaCO2 did not differ between the NIV and invasive-MV patients. However, 
while baseline PaCO2 in mild ARDS was higher in NIV compared to invasive-MV patients (48±18 
vs 41±10 mmHg, p=0.002), PaCO2 in severe ARDS was lower in NIV (43±14 vs 52±18 mmHg, 
p<0.001) compared to invasive-MV. In contrast to patients managed with invasive-MV, where 
PaCO2 significantly increased with greater ARDS severity (p < 0.001), the PaCO2 in the NIV group 
did not change (p = 0.134) with severity category (Table 1 and Figure 2).  
 
NIV Failure versus Success 
Among the 349 NIV patients without pre-intubation treatment limitations, 131 (37.5%) failed NIV 
(Table 3), after a mean of … ± … days. A multivariate Cox model revealed that higher non-
pulmonary SOFA score, lower PaO2/FiO2 and the percentage increase of PaCO2 over the first two 
days of treatment were independently associated with NIV failure within 28 days from AHRF onset 
(Table E4 in the online data supplement). 
 
Effect of Intubation on Physiological Variables 
Table E5 in the online data supplement and figure 2C show the comparison, for physiological 
variables, between the last available recording of NIV and the first available recording during 
invasive-MV. After intubation, both PaO2/FiO2 (152±68 vs 182±95 mmHg, p<.001) and PaCO2 
significantly increased. After initiation of invasive-MV, patients were managed with a higher PEEP 
and had lower respiratory rates, received lower tidal and minute volumes, compared to pre-
intubation values.  
 
Outcomes in NIV patients 
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Crude ICU and hospital mortalities were not significantly different between the NIV and the 
invasive-MV patients (Table 2 and Figure E2 in the online data supplement).  
Patients that failed NIV were more severely ill (Table 3) and had significantly worse ICU (42.7% vs 
10.6%, p-value<0.001) and hospital mortality compared to those that were successfully managed 
with NIV (Table 3). 
 
In a multivariate Cox regression model adjusting for covariates significantly associated with 
outcome (see Table E6 in the online data supplement, NIV use was independently associated with 
increased ICU (but not hospital) mortality rate (HR 1.446; [1.159-1.805]). Furthermore, we 
matched 353 NIV with invasive-MV patients using propensity score (Table E2 in the online data 
supplement). The two matched populations were homogeneous for demographic characteristics, 
comorbidities and severity of organ failures (Table E2 in the online data supplement). ICU and 
hospital mortality rates did not differ (Table 4). Kaplan-Meier survival estimates for invasive-MV 
and NIV patients of the matched samples were non significantly (p =0.093) different (Figure 3). In 
the subset of patients with a PaO2/FiO2 ratio<150, ICU mortality was 36.2 % with NIV compared to 
24.7 % with invasive-MV (p =0.033) (Table 4). Figure 3 shows survival curves in NIV and 
invasive-MV groups for matched patients with a PaO2/FiO2 higher and lower than 150 mmHg.  
Table E7 in the online data supplement, shows the comparison between survivors and non- 
survivors at hospital discharge, in NIV patients. Non-survivors were older, with a higher prevalence 
of immunosuppression or neoplastic disease and had a higher non-pulmonary SOFA score.  
Moreover, non-survivors had, on the day of ARDS diagnosis, a lower PaO2/FiO2 and higher 
respiratory rate than survivors. A multivariate Cox model performed on baseline characteristics in 
the NIV group showed that chronic heart failure, presence of hematologic or neoplastic disease, 
chronic liver failure, age, ARDS severity, percentage decrease of PaO2/FiO2 ratio between days 1 
and 2, total respiratory rate and non-pulmonary SOFA score were each independently associated 
with risk of in-hospital death (Table E8). 
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DISCUSSION 
 
Of the 2,813 patients that were diagnosed with ARDS criteria within two days of developing AHRF 
enrolled into the LUNG SAFE study, 436 (15.5%) were managed with NIV on days 1 and 2. NIV 
patients were older and had more comorbidities, but had lower non-pulmonary SOFA scores 
compared to invasive-MV patients. NIV failure occurred in 134 (30.7%) patients, necessitating 
change to invasive-MV. Classification of ARDS severity based on PaO2/FiO2 ratio categories was 
indicative of a higher intensity of treatment and worse outcome, as is seen in ARDS patients 
managed with invasive-MV. Of interest, NIV applications rates were similar across the ARDS 
severity categories. While crude mortality was not different, after adjustment for covariates NIV 
was associated with increased ICU (but not hospital mortality). This finding appeared confined, in 
the propensity matched analysis, to the more severe patients, i.e. those with a PF ratio < 150 mHg. 
The finding that NIV use was similar across the ARDS severity categories was surprising given the 
fact that recommendations for NIV use in ARDS suggest that its use be confined to mild ARDS 
(18). While success rates of NIV in mild ARDS were 78%, this decreased to 58% in moderate and 
53% in severe ARDS, consistent with previous findings (23). Although NIV has been shown to be 
beneficial in the subgroup of patients with immunosuppression/neoplastic diseases (8-12), the 
presence of these diseases were not associated with a greater use of NIV in our patients. NIV use 
appeared associated with other factors, such as pre-existing COPD, congestive heart failure and 
chronic renal failure. 
 
While the Berlin definition clearly acknowledges that ARDS diagnosis can be fulfilled by patients 
undergoing NIV, the definition is less clear concerning how ARDS severity should be determined 
in these patients. While some authors used the PaO2/FiO2 severity bands  also for NIV patients (26), 
others considered that NIV patients with PaO2/FiO2 <200 mmHg could not be classified according 
to Berlin definition and these patients were excluded from analysis (24). Our results support the use 
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of PaO2/FiO2 bands to classify NIV patients in mild, moderate and severe: worsening ARDS 
categories were associated with more prolonged and aggressive ventilator support, and worse 
patient outcomes.  
 
The use of NIV was associated with important differences in the clinical management of patients 
with ARDS, which might be, in part, explained by the low recognition of ARDS in these patients. 
NIV patients received lower levels of PEEP (with a median value of 7 cmH2O) in all the ARDS 
categories and a predominant use of FiO2 to correct hypoxemia. This finding is clinically relevant, 
since application of higher levels of PEEP has been associated with improved outcomes in patients 
with moderate to severe ARDS (27). While the use of lower PEEP may be seen as “inherent” to the 
use of NIV, due to constraints in increasing airway pressure, our results also highlight the effects of 
the lack of control over respiratory drive. Minute ventilation was higher in NIV patients as a result 
of higher respiratory rate and tidal volumes. Tidal volumes were also higher than the 6-8 ml/kg of 
ideal body weight recommended for lung protective ventilation. This data should be interpreted 
cautiously, since it was measured only in a subset of NIV patients and limitations exist regarding 
the accuracy of measurement of tidal volume during NIV. In NIV patients, minute ventilation 
increased with greater ARDS severity during NIV with no significant difference in PaCO2, 
suggesting that the increased patient respiratory drive compensated for the increased dead space. In 
patients failing NIV, institution of invasive-MV was associated with increased PEEP, decreased  
oxygen fraction, and improved PaO2/FiO2 ratios, as well as decreases in tidal volume and 
respiratory rate leading to a ≈30% drop of minute ventilation, resulting in an increased PaCO2. 
Ventilator settings in patients transitioned to invasive-MV were closer to ‘protective’ settings than 
those seen prior to NIV failure, suggesting that institution of invasive-MV (which might have 
required increased sedation) facilitated better control of tidal volume and airway pressures, possibly 
decreasing the risk of lung injury.  
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NIV failure was associated with a substantial increase in the risk of death, with mortality higher 
than for severe ARDS managed with invasive-MV. While this finding may reflect the fact that these 
patients were sicker at commencement of NIV, and worsened over time, it underlines the need for 
careful patient selection when considering NIV use in ARDS. Factors independently associated 
with NIV failure included higher non-pulmonary SOFA score and higher respiratory rate. 
Evaluating the patient’s response to NIV is also important, with the percentage increase of PaCO2 
over the first two days of treatment also associated with NIV failure. A decline of PaO2/FiO2 ratio 
between day 1 and 2 of treatment was independently associated with an increased mortality in NIV 
patients. These parameters could be used to stratify patients when deciding to treat patients with 
NIV or in deciding to terminate NIV and proceed to invasive-MV. 
 
Of concern is the finding that NIV use appears to be associated with increased ICU mortality. After 
adjusting for potential confounders, a patient treated with NIV at ARDS onset appeared to have a 
30% increased risk of dying in ICU compared to a similar patient treated with invasive-MV. This 
result should be interpreted cautiously, since it was not confirmed for the hospital mortality and is 
partly discrepant with the propensity matched analysis (affected by a lower power due to the 
smaller number of patients included). Finally, while the model did not highlight any effect of the 
interaction between NIV and PaO2/FiO2 ratio on mortality, in the propensity matched cohort, the 
ICU mortality was significantly higher for NIV than for invasive-MV in the cohort of patients with 
PaO2/FiO2 <150 mmHg. In this respect our data are consistent with previous reports showing an 
increase in NIV failure rates, in patients with a PaO2/FiO2 ratio ≤ 150 mmHg (28).  
 
The LUNG SAFE study represents one of the largest prospective datasets of ARDS patients treated 
with NIV. Nonetheless, it does have limitations. To limit the burden on investigators, data were 
collected as often as once/day and we did not collect hours of duration of NIV treatment, a factor 
previously thought to be important in NIV success/failure (29). For this reason, we conservatively 
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considered “NIV patients” as only those undergoing this treatment on days 1 and 2. Patients treated 
with NIV for a shorter period and subsequently intubated were considered in the invasive MV 
group. This was done for consistency with our previous work and to avoid considering as “NIV 
patients” those receiving only a short NIV trial, or who entered the ICU under NIV, and were 
subsequently intubated quickly. Clearly, a drawback of this approach is the potential 
underestimation of NIV failure rate. We did not include patients undergoing high flow oxygen, as 
these patients did not fulfill the Berlin criteria for ARDS (30, 31). We did not collect data on the 
type of interface used for NIV, which may be a potentially important determinant of NIV success 
(32). Moreover we did not collect patients’ severity scores, such as APACHE and SAPS, but relied 
on the SOFA score to characterize the non –pulmonary severity of illness severity. Finally, although 
we collected data regarding the presence of treatment limitation decisions, we cannot completely 
exclude the possibility that clinicians may have been reluctant to use invasive-MV in patients at 
higher risk of dying due to pre-existing medical conditions (as suggested, for example, by older age 
of the NIV patients). 
 
In conclusion, in a large cohort of ARDS patients, NIV was used in 15% of cases, and was used to a 
similar extent across the severity categories. Use of NIV was independently associated with an 
under-recognition of ARDS by clinicians. NIV failure occurred in more than one-third of ARDS 
patients and in almost half of patients with moderate and severe ARDS. Mortality rates in patients 
that failed NIV were high. Of concern, NIV was associated with a worse adjusted ICU mortality 
than invasive-MV in patients in patients with a PaO2/FiO2 lower than 150 mmHg. These findings 
raise further concerns regarding NIV use in this patient group. 
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Figure legends: 
Figure 1: Flowchart of the study population  
* Treatment limitation before AHRF onset or within 28 day; † Failure of non-invasively ventilation 
was evaluated within 28 days from AHRF onset; ‡ We reported vital status at hospital discharge 
censored at day 90 after AHRF onset. Vital status was unknown for 9 patients: 8 invasively 
ventilated and 1 non-invasively ventilated within 48 hours from AHRF onset. 
Figure 2: Differences in physiological variables for patients treated with invasive and non-invasive 
ventilation. Panel A: While for mild ARDS PaCO2 was significantly higher in patients managed 
with non-invasive ventilation, the opposite was true for severe ARDS, where PaCO2 was lower in 
patients treated with non-invasive ventilation. * p-value < 0.05, comparison between Invasive-MV 
and NIV group. Panel B: While PaO2/FiO2 was not different over the first two days in patients 
managed with non-invasive and invasive ventilation, this improved more rapidly in the patients 
managed with invasive ventilation (for NIV n=422, 421, 382, 293, 228, 149, 94, 50, 18, from day 1 
to 28). * p-value < 0.05, comparison between Invasive-MV and NIV group. Panel C: relative 
differences (increase of decrease) of selected physiological variables between the last day of non-
invasive ventilation and the first day of invasive ventilation, in the subset of patients with non-
invasive ventilation failure. † p-value < 0.05, no change in the variable. 
Figure 3: Kaplan-Meier survival curves in the propensity score matched samples of patients 
managed with non-invasive and invasive ventilation. Panels A, B, C report respectively the survival 
over time in the entire sample (N=706), in matched sample with PaO2/FiO2 ratio < 150 mmHg 
(N=184) and in matched sample for PaO2/FiO2 ratio ≥ 150 mmHg (N=194). Note: vital status was 
evaluated at hospital discharge. Patients were censored on day 28 from AHRF onset. Patients 
discharged alive from hospital before the day 28 from AHRF onset were considered alive at day 28. 
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Table 1. Demographic and clinic characteristics of study population (stratified by ARDS severity and ventilation) at baseline (ARDS onset). 
  ARDS – Mild ARDS – Moderate ARDS - Severe ARDS p-value 
within NIV 
p-value 
within invasive-MV   NIV Invasive -MV NIV 
Invasive 
-MV NIV 
Invasive 
-MV NIV 
Invasive 
-MV 
N 119 714 232 1,106 85 557 436 2,377 - - 
% within ARDS severity  14.3 85.7 17.3 82.7 13.2 86.8 15.50 84.50 - - 
Male, n (%) 58 (48.7) 439 (61.5)* 150 (64.7) 683 (61.8) 49 (57.6) 350 (62.8) 257 (58.9) 1,472 (61.9) 0.016 0.875 
Age (years), median [IQR] 71 [59 - 77] 64 [51 - 75]* 68 [56 - 79] 64 [52 - 74]* 64 [49 - 76] 58 [44 - 70]* 68 [54 - 78] 63[50 - 73]* 0.110 <.001 
Risk factors for ARDS, n (%)         0.4775 <.0001 
None 19 (16.0) 69 (9.7)* 30 (12.9) 85 (7.7)* 13 (15.3) 36 (6.5)* 62 (14.2) 190 (8.0)*   
Non-pulmonary 15 (12.6) 180 (25.2)* 28 (12.1) 219 (19.8)* 5 (5.9) 81 (14.5)* 48 (11.0) 480 (20.2)*   
Pulmonary 85 (71.4) 465 (65.1) 174 (75.0) 802 (72.5) 67 (78.8) 440 (79.0) 326 (74.8) 1,707 (71.8)   
Comorbities, n (%)           
Diabetes 28 (23.5) 153 (21.4) 52 (22.4) 253 (22.9) 18 (21.2) 109 (19.6) 98 (22.5) 515 (21.7) 0.924 0.298 
Chronic renal failure 19 (16.0) 77 (10.8) 31 (13.4) 111 (10.0) 12 (14.1) 36 (6.5)* 62 (14.2) 224 (9.4)* 0.803 0.021 
Heart failure 22 (18.5) 74 (10.4)* 34 (14.7) 105 (9.5)* 10 (11.8) 45 (8.1) 66 (15.1) 224 (9.4)* 0.400 0.382 
Chronic liver failure 4 (3.4) 31 (4.3) 2 (0.9) 45 (4.1)* 3 (3.5) 27 (4.8) 9 (2.1) 103 (4.3)* 0.109 0.763 
Neoplasm or immunosuppression  20 (16.8) 147 (20.6) 62 (26.7) 209 (18.9)* 17 (20.0) 129 (23.2) 99 (22.7) 485 (20.4) 0.089 0.125 
COPD 46 (38.7) 132 (18.5)* 70 (30.2) 239 (21.6)* 19 (22.4) 101 (18.1) 135 (31.0) 472 (19.9)* 0.043 0.134 
Home ventilation 8 (6.7) 13 (1.8)* 10 (4.3) 20 (1.8)* 3 (3.5) 5 (0.9) 21 (4.8) 38 (1.6)* 0.502 0.321 
Parameters at day of ARDS onset, mean ± SD         
PaO2 (mmHg) 109.4 ± 42.1 118.2 ± 46.6 80.7 ± 21.7 90.7 ± 28.3* 67.7 ± 14.0 66.3 ± 15.2 86.0 ± 31.6 93.2 ± 37.9* <.001 <.001 
FiO2 0.45 ± 0.18 0.48 ± 0.19* 0.57 ± 0.16 0.62 ± 0.19* 0.88 ± 0.13 0.90 ± 0.15* 0.60 ± 0.22 0.65 ± 0.24* <.001 <.001 
PaO2/FiO2 (mmHg) 243 ± 29 246 ± 28 146 ± 29 149 ± 28 79 ± 17 75 ± 17 160 ± 63 161 ± 68 <.001 <.001 
pH 7.37 ± 0.09 7.36 ± 0.10 7.37 ± 0.10 7.33 ± 0.12* 7.41 ± 0.09 7.27 ± 0.14* 7.38 ± 0.10 7.33 ± 0.12* 0.007 <.001 
PaCO2 (mmHg) 48 ± 18 41 ± 10* 47 ± 18 46 ± 15 43 ± 14 52 ± 18* 46 ± 17 46 ± 15 0.134 <.001 
Base Excess (mmol/L) 1.49 ± 7.50 -1.93 ± 6.23* 0.42 ± 6.53 -2.23 ± 6.85* 1.18 ± 5.99 -2.74 ± 8.11* 0.86 ± 6.72 -2.26 ± 6.99* 0.181 0.009 
PEEP (cmH2O) 7 ± 2 7 ± 3 7 ± 2 8 ± 3* 7 ± 2 10 ± 4* 7 ± 2 8 ± 3* 0.042 <.001 
Total Respiratory rate (breaths/min) 24 ± 7 19 ± 6* 27 ± 7 21 ± 6* 27 ± 6 23 ± 14* 26 ± 7 21 ± 9* <0.001 <.001 
Minute ventilation (L/min)  12.19 ± 5.24 9.13 ± 2.93* 13.63 ± 5.74 9.50 ± 3.10* 13.29 ± 4.90 9.91 ±3.15* 13.18 ± 5.47 9.49 ± 3.07* 0.057 <.001 
Tidal Volume (ml/kg PBW)  8.73 ± 2.85 7.76 ± 1.77* 8.37 ± 2.84 7.60 ± 1.92* 7.98 ± 2.62 7.46 ± 1.93* 8.39 ± 2.81 7.61 ± 1.88* 0.348 0.007 
Non-pulmonary SOFA score adj. 3 ± 3 7 ± 4* 3 ± 3 7 ± 4* 3 ± 3 7 ± 4* 3 ± 3 7 ± 4* 0.548 0.370 
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Use of vasopressors, n (%) 16 (14.4) 342 (51.8)* 37 (17.6) 575 (55.2)* 9 (11.8) 325 (61.2)* 62 (15.6) 1,242 (55.6)* 0.453 0.005 
Use of CPAP, n (%) 35 (29.4) - 65 (28.0) - 23 (27.0) - 123 (28.2) - 0.930 - 
Abbreviations: IQR: interquartile range; MV: mechanical ventilation; NIV: Non-invasive ventilation; SD: standard deviation; COPD: Chronic Obstructive Pulmonary Disease; PBW: 
predicted body weight; PEEP: Positive end-expiratory pressure; SOFA: Sequential Organ Failure Assessment; CPAP: continuous positive airway pressure. 
* p-value < 0.05, comparison vs NIV group with same ARDS severity.  
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Table 2. Events occurred during follow-up in study population (stratified by ARDS severity and ventilation). 
  ARDS - Mild ARDS – Moderate ARDS - Severe ARDS p-value 
within NIV 
p-value 
within invasive-MV   NIV Invasive-MV NIV Invasive-MV NIV Invasive-MV NIV Invasive-MV 
N 119 714 232 1.106 85 557 436 2.377 - - 
Clinical recognition of ARDS, n (%)           
At study entry           
At any time 41 (34.5) 366 (51.3)* 122 (52.3) 722 (65.3)* 47 (55.3) 437 (78.5)* 210 (48.2) 1,525 (64.2)* 0.002 <.001 
Patients with treatment limitation, n (%) 27 (22.7) 171 (23.9) 68 (29.3) 272 (24.6) 29 (34.1) 135 (24.2) 124 (28.4) 578 (24.3) 0.186 0.951 
Length of stay (from ARDS onset) in ICU (days), median [IQR] 
        
all patients 
6 
[3 -10] 
8 
[4 - 16]* 
8 
[4 - 13.5] 
10 
[5 - 19]* 
7 
[4 - 12] 
10 
[4 - 18]* 
7 
[4 - 12] 
9 
[5 - 18]* 
0.032 0.019 
alive patients at ICU discharge 
5 
[3 -8] 
9 
[5 - 18]* 
8 
[4 - 13] 
11 
[6 - 20]* 
7 
[4 - 13] 
13 
[7 - 23]* 
7 
[4 -12] 
11 
[6 - 20]* 
0.002 <.001 
ICU mortality, n (%) 26 (21.8) 191 (26.8) 64 (27.8) 351 (31.7) 34 (40.0) 221 (39.7) 124 (28.4) 763 (32.1) 0.017 <.001 
Hospital mortality, n (%) 36 (30.3) 249 (34.9) 83 (35.8) 446 (40.3) 37 (43.5) 257 (46.4) 156 (35.8) 952 (40.1) 0.130 <.001 
Abbreviations: ARDS: Acute respiratory Distress Syndrome; MV: mechanical ventilation; NIV: Non-invasive ventilation; IQR: interquartile range; ICU: Intensive Care Unit;  
* p-value < 0.05, comparison vs NIV group with same ARDS severity. 
Note: vital status was evaluated at ICU / hospital discharge. Patients who were still in ICU / hospital were censored on day 90 from AHRF onset.  
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Table 3. Demographic and clinical characteristics of ARDS NIV patients at baseline (ARDS onset). 
Population was stratified according the NIV treatment outcome (success-failure) occurred in ICU 
during 28 days from AHRF onset. 
 
Abbreviations: ARDS: Acute respiratory Distress Syndrome; NIV: Non-invasive ventilation; IQR: interquartile range; 
SD: standard deviation; COPD: Chronic Obstructive Pulmonary Disease; PBW: predicted body weight; PEEP: 
 
ARDS - NIV 
(without treatment limitations) p-value 
 Success Failure* 
Patients, n (%)   0.001 
All 218 (62.5) 131 (37.5)  
Mild ARDS  77 (77.8) 22 (22.2)  
Moderate ARDS  105 (57.7) 77 (42.3)  
Severe ARDS  36 (52.9) 32 (47.1)  
Male, n (%) 129 (59.2) 80 (61.1) 0.727 
Age, median [IQR] 66.5 [52 - 78] 63.0 [53 - 74] 0.081 
ICU mortality, n (%) 23 (10.6) 56 (42.7) <.001 
Hospital mortality, n (%) 35 (16.1) 59 (45.4) <.001 
Clinical recognition of ARDS, n (%)    
At study entry    
At any time    
Risk factors for ARDS, n (%) 
  
0.2114 
None 33 (15.1) 12 (9.2)  
Non-pulmonary 27 (12.4) 14 (10.7)  
Pulmonary 158 (72.5) 105 (80.1)  
Comorbidities, n (%) 
   
Diabetes 56 (25.7) 21 (16.0) 0.035 
Chronic renal failure 36 (16.5) 11 (8.4) 0.032 
Heart failure (NYHA III-IV) 28 (12.8) 18 (13.7) 0.811 
Chronic liver failure 4 (1.8) 2 (1.5) 1.000 
Active neoplasm or immunosuppression or hematologic 
neoplasm 
42 (19.3) 34 (26.0) 0.143 
COPD 74 (33.9) 33 (25.2) 0.086 
Home ventilation 13 (6.0) 5 (3.8) 0.380 
Parameters at day of ARDS onset, mean ± SD 
   
PaO2 (mmHg) 88.6 ± 31.6 83.1 ± 30.5 0.097 
FiO2 0.58 ± 0.22 0.63 ± 0.21 0.007 
PaO2/FiO2 ratio (mmHg) 171 ± 65 145 ± 60 <.001 
pH 7.38 ± 0.09 7.38 ± 0.09 0.967 
PaCO2 (mmHg) 48 ± 17 44 ± 17 0.009 
Base Excess (mmol/L) 1.91 ± 6.73 -0.02 ± 6.83 0.002 
PEEP (cmH2O) 7 ± 2 7 ± 2 0.478 
Total Respiratory rate (breaths/min) 25 ± 6 27 ± 8 0.012 
Minute ventilation (L/min) 12.71 ± 5.07 14.03 ± 6.25 0.107 
Tidal Volume (ml/kg PBW)  8.38 ± 2.60 8.65 ± 3.11 0.795 
Non-pulmonary SOFA score adjusted 2 ± 3 3 ± 3 0.019 
Patients under pressors agents, n (%) 23 (11.7) 18 (15.1) 0.376 
Use of CPAP, n (%) 59 (27.1) 35 (26.7) 0.907 
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Positive end-expiratory pressure; SOFA: Sequential Organ Failure Assessment; CPAP: continuous positive airway 
pressure. 
Note 1: patients with pre-intubation treatment limitations were excluded from this analysis.  
Note 2: vital status was evaluated at ICU / hospital discharge. Patients who were still in ICU / hospital were censored on day 90 
from AHRF onset.  
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Table 4. Effect of treatment and clinical parameters at ARDS onset for invasive-MV and NIV 
patients in the propensity score matched sample. 
 
Invasive-MV patients 
(n=353) 
NIV patients 
(n=353) 
p-value 
ARDS severity at onset, n (%)    
Mild  100 (28.33) 101 (28.61) 1.000 
Moderate  184 (52.12) 165 (46.74) 0.195 
Severe  69 (19.55) 87 (24.65) 0.127 
Patients with PaO2/FiO2 ratio < 150 mmHg at ARDS onset, 
n (%) 
174 (49.29) 174 (49.29) 1.0000 
Parameters at ARDS onset, mean±SD    
pH  7.35 ± 0.11 7.38 ± 0.09 0.001 
FiO2 0.66 ± 0.24 0.60 ± 0.22 0.001 
SPO2 (%) 94.53 ± 5.51 94.99 ± 3.85 0.660 
Total Respiratory Rate (breaths/min) 20.66 ± 6.46 25.63 ± 7.01 <.001 
PEEP (cmH2O) 8.09 ± 3.1 7.02 ± 1.95 <.001 
Peak Inspiratory Pressure (cmH2O) 26.77 ± 7.66 17.43 ± 7.22 <.001 
PaO2 (mmHg) 94.64 ± 40.32 87.96 ± 32.55 0.031 
PaCO2 (mmHg) 46.5 ± 14.41 45.8 ± 17.36 0.320 
PaO2/FiO2 (mmHg) 157.62 ± 65.58 160.94 ± 64.29 0.492 
Tidal Volume (ml/Kg PBW) 7.53 ± 1.75 8.46 ± 2.77 0.001 
Minute ventilation (L/min) 9.31 ± 2.90 13.26 ± 5.60 <.001 
Base excess (mmol/L) -0.74 ± 5.93 0.60 ± 6.55 0.002 
HCO3 (mmol/L) 24.39 ± 5.65 25.4 ± 6.95 0.086 
Non-pulmonary SOFA adjusted 3.26 ± 2.82 3.19 ± 2.84 0.423 
Δ (%)* PaO2/FiO2 ratio 36.31 ± 76.76 28.17 ± 76.77 0.063 
Δ (%)* PaCO2 -0.3 ± 29.86 3.37 ± 25.92 0.025 
Use of vaso pressors, n (%) 80 (24.32) 49 (15.03) 0.005 
Duration of mechanical ventilation (days)    
all patients    
ICU survivors    
Length of ICU stay (days)    
all patients    
ICU survivors    
All-cause in-ICU mortality, n (%)    
all patients 92 (26.06) 99 (28.05) 0.608 
matched patients  with PaO2/FiO2 ratio<150 mmHg 43 (24.71) 63 (36.21) 0.033 
All-cause in-hospital mortality, n (%)    
all patients 115 (32.76) 117 (33.24) 0.871 
matched patients  with PaO2/FiO2 ratio<150 mmHg 55 (31.61) 66 (38.15) 0.224 
Abbreviations: ARDS: Acute respiratory Distress Syndrome; MV: mechanical ventilation; NIV: Non-invasive 
ventilation; IQR: interquartile range; SD: standard deviation; PBW: predicted body weight; PEEP: Positive end-
expiratory pressure; SOFA: Sequential Organ Failure Assessment. 
* Delta (Δ) was evaluated as difference between the value measured at the second day from ARDS onset and those measured at the 
ARDS onset day. Percentage was evaluated as rate between Δ and value measured at the ARDS onset day.  
Note 1: statistical tests accounted for the matched nature of the sample (paired t-test or Wilcoxon Signed Ranks test for continuous 
variables, McNemar’s test for dichotomous variables).  
Note 2: for 3 patients (2 Invasive-MV and 1 NIV) vital status at hospital discharge were missing. 
Note 3: vital status was evaluated at ICU / hospital discharge. Patients who were still in ICU / hospital were censored on day 90 
from AHRF onset.  
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